Skip to Content Skip to Search

A new consumer healthcare company

GSK’s Consumer Healthcare business is on track to become an independent company through a proposed demerger from GSK in mid-2022. The new business, to be named Haleon, is expected to be a world-leader in consumer healthcare, offering the prospect of attractive organic sales growth, operating margin expansion and consistent high cash generation.

Led by its purpose to deliver better everyday health with humanity, it will be strongly positioned to play a vital role in a growing sector that is more relevant than ever. Haleon will have a world-class portfolio of category-leading global brands, including Sensodyne, Voltaren, Panadol and Centrum, brands that are trusted by healthcare professionals, customers and people worldwide to improve the health and wellbeing of individuals and their communities. 

FAQs for shareholders

Find the answers to our frequently asked questions about what the demerger means for your GSK shareholding and receiving Haleon shares.

GSK announces appointments to Designate Haleon Board

On 15 March 2022 we announced the appointment of six directors to the designate Board of Haleon. The new appointments follow Sir Dave Lewis’s appointment as Chair Designate in December 2021 – who has led this search and selection process – and represent further progress to create a new, qualified Board for Haleon with the appropriate mix of skills, experience, diversity, and continuity. Read the press release for full details.

Consumer Healthcare Capital Markets Day

GSK's Consumer Healthcare Capital Markets Day took place on Monday 28 February 2022. This event provided details on our strategy, brands, capabilities and operations, as well as detailed financial information and future growth ambitions ahead of the proposed listing on the London Stock Exchange following the anticipated demerger from GSK mid-2022.

Find out more about the event

Designate Chair

Man in a suit smiling
Sir Dave Lewis, Chair Designate

GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company


Press release

Designate Executive Leadership Team

Speeches and presentations

Redburn CEO conference 2021- Brian McNamara (01 December 2021)

Brian McNamara, CEO of GSK Consumer Healthcare participated virtually in the 2021 Redburn CEO Conference. He provided an overview of our business and broader industry.

 Tobias Hestler
UBS European Conference 2021 – Tobias Hestler (09 November 2021)

Tobias Hestler, CFO GSK Consumer Healthcare, spoke at the UBS European Conference hosted by analyst Guillaume Delmas.

Click here to view video

Tobias Hestler
Bernstein Annual Pan European Strategic Decisions Conference – Tobias Hestler (22 September 2021)

Tobias Hestler, CFO for GSK Consumer Healthcare participated in the Bernstein Annual Pan European Strategic Decisions Conference.

Click here to view video

Brian McNamara
Barclay’s Global Consumer Staples conference – Brian McNamara (10 September 2021)

Brian McNamara, CEO GSK Consumer Healthcare, joined a virtual fireside chat hosted by Barclay’s analyst, Iain Simpson. He provided an overview of the Consumer Healthcare business and our category leading brands.

Click here to view video

Exane BNP Paribas 23rd European CEO Conference – Brian McNamara (10 June 2021)

Brian McNamara, CEO, GSK Consumer Healthcare, presented at the conference and provided an introduction to GSK Consumer Healthcare and outlined our purpose, strategy, category-leading brands and capabilities, as well as an overview of the consumer healthcare sector.

Click here to download slides

Investor contacts

Sonya Ghobrial
Head of IR Consumer Healthcare GSK


Media contacts

Global Headquarters (London, UK)

Tim Foley
VP, Global Corporate Media Relations

Madeleine Breckon
Director, Global Corporate Media Relations, Pharmaceuticals

Simon Moore
Director, Global Corporate Media Relations, Vaccines and Global Public Health

Tel: +44 (0)20 8047 5502

USA (Philadelphia)

Kristen Neese
VP, Global Product & Pipeline Communications & US Corporate Communications

Kathleen Quinn
Head, US Corporate Communications

Haleon will continue to use and protect your personal information in accordance with the same notices and practices in effect prior to our divestiture from GSK. The GSK Privacy Notice explains how we collect, use, share and protect your personal information, as well as how you can exercise your rights in regard to your personal information. Upon divestiture, Haleon will update the Privacy Notice to identify the new company (“Haleon”) and to let you know how to reach the new company with questions or requests related to your personal information.